Shenzhen Hepalink Pharmaceutical Group: 2024 Interim Performance Forecast
Shenzhen Hepalink Pharmaceutical's Profit to Soar Nearly 500% in H1
Shenzhen Hepalink Pharmaceutical Group (HKG:9989, SHE:002399) expects a 421-496% boost in attributable profit for the six months ended June 30 to between around 642.3 million yuan and 734.8 million
Shenzhen Hepalink Sees Soaring H1 2024 Profits
Express News | Shenzhen Hepalink Pharmaceutical Sees Hy Net Profit Attributable Between RMB642.28 Million to RMB734.82 Million
HEPALINK: POSITIVE PROFIT ALERT - ANNOUNCEMENT FOR THE ESTIMATED 2024 INTERIM RESULTS
Guoyuan Securities: Each overseas business model has its own advantages and disadvantages. Pharmaceutical companies should choose according to their own size.
Leveraging external resources is currently the most mainstream mode for Chinese pharmaceutical companies to expand overseas, which is suitable for companies with limited resources and in need of international experience accumulation, but it also means that the company's voice will be weakened and the relative benefits of sharing will be limited.
Hong Kong stock concept tracking | Innovative drug policy released, medical companies will speed up improvement in the second half of the year (with concept stocks).
Recently, several domestic heavyweight innovative drugs have been approved, and heavyweight data has been successively announced by ASCO, ESMO, ADA, and EHA. The negotiation rules for payment-side medical insurance tend to be clear and mild, and the regulatory side promotes the industry around clinical value. Domestic new drugs have entered the 2.0 era.
Hong Kong stock market concept tracking | Heavy policies supporting the development of innovative drugs are introduced! The industry is expected to enter the fast lane of development (with concept stocks).
On July 5th, the State Council's executive meeting discussed and deployed the work related to promoting high-quality development of the digital economy, and approved the Implementation Plan for Supporting the Development of Innovative Drugs throughout the Whole Chain.
Hepalink (09989.HK) received a shareholding increase of 452,500 shares from shareholder Hong Zejun.
According to the latest equity disclosure information from the Hong Kong Stock Exchange, on June 25, 2024, Hepalink (09989.HK) shareholder Hong Zejun increased his shareholding by purchasing 452,500 shares at an average price of HKD 3.29 per share, involving approximately HKD 1,488,700. After the shareholding, Hong Zejun's latest number of shares held increased from 15.43 million to 15.88 million, and the shareholding ratio increased from 6.80% to 7.01%.
Shenzhen Hepalink Pharmaceutical Group (SZSE:002399) Investors Are Sitting on a Loss of 51% If They Invested Five Years Ago
While not a mind-blowing move, it is good to see that the Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SZSE:002399) share price has gained 14% in the last three months. But that can't change t
Shenzhen Hepalink Shareholders Approve Key Resolutions
A record high! The total number of clinical trials exceeded 4,000 in 2023
According to the report, in 2023, the total number of clinical trials registered on the drug clinical trial registration and information disclosure platform surpassed 4,000 for the first time, reaching 4,300 (in terms of CTR), the highest total number of registrations in history, an increase of 26.1% over the total number of registrations in 2022.
Hyperlink (002399.SZ/9989.HK): 2024Q1 net profit to mother increased 133% year-on-year, steady operation continued to improve
In an environment where the external market is still full of uncertainty, the disclosure of the 2023 report and 2024 quarterly report related to A-shares has come to an end. Looking back at 2023, companies related to the heparin industry faced quite a few challenges under stress tests in the face of declining pig cycles. However, at the beginning of 2024, along with the gradual stabilization of the bottom of pig prices, some leading companies have improved significantly and shown strong resilience. Among them, Hapley, a leading company in the heparin industry, also handed over a report in the first quarter of 2024 with a 133% year-on-year increase in net profit, outperforming the industry's performance during the same period. Hypri publishes quarterly report
Closing up 42% at the end of the session, is it still too early to say that Junshengtai Pharmaceutical-B (02511) broke out of the trough?
With high investment in R&D, capital consumption will also increase. Whether the current cash can support the commercialization of Junshengtai's core products is still unknown.
Why Investors Shouldn't Be Surprised By Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s (SZSE:002399) Low P/S
You may think that with a price-to-sales (or "P/S") ratio of 2.8x Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SZSE:002399) is a stock worth checking out, seeing as almost half of all the Pharmac
Changes in Hong Kong stocks | Hapley (09989) A shares rose or stopped, and H shares once rose more than 11%, net profit to mother increased 1.33 times year-on-year in the first quarter
Hypry (09989) A-shares rose to a halt. As of press release, H shares rose 8.59% to HK$3.54, with a turnover of HK$124.367 million.
HEPALINK: 2023 Annual Report
Hyperion (09989) plans to renew Ernst & Young Huaming and EY as auditors
Haipuri (09989) issued an announcement. Shenzhen Haipuri Pharmaceutical Group Co., Ltd. was announced on April 29, 2024...
Hapley (09989) announced first-quarter results, net profit of 155 million yuan, up 133% year-on-year
Hapley (09989) announced its results for the first quarter of 2024, with revenue of 1,373 billion yuan, an increase of 5...
HEPALINK: 2024 FIRST QUARTERLY REPORT
No Data